FDA New Drug and Biologic Approvals, 2018 Midyear Review

Mary L Windle, PharmD


August 01, 2018

In This Article

New Indications

HIV-1: Truvada (emtricitabine/tenofovir DF)

Indicated in combination with safer sex practices for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 expanded to include at-risk adolescents weighing at least 35 kg.

Hospital-Acquired/Ventilator-Associated Bacterial Pneumonia: Avycaz (ceftazidime/avibactam)

New indications for adults with hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia (VABP).


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.